Endocrine Abstracts

Objectives: Copper-64 (64Cu, T1/2=12.7 h; Eβ+ max =0.65 MeV (17.9%); Eβ− max =0.57 MeV (39%)) is suitable for in-vivo PET imaging. Prostate specific membrane antigen (PSMA) is significantly over-expressed in undifferentiated prostate cancer tissue. We report the initial molecular imaging results with 64Cu-PSMA PET/CT in patients with prostate cancer.Methods: 64Cu labeled PSMA (mean administered ra...

Aim: To analyze the safety, efficacy and dosimetry of Lu-177 labeled prostate specific membrane antigen (PSMA) ligand 617 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC), in comparison with Lu-177 PSMA I&T.Methods: Lu-177 PSMA-617 radioligand therapy (PRLT) was performed in 64 mCRPC patients. The median administered activity per treatment was 6 GBq. Ga-68 PSMA PET/CT was used for patient selection and follow-up. H...